Kristin G I Mohn
Overview
Explore the profile of Kristin G I Mohn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meln I, Cnossen V, Corti N, Andeweg A, Baay M, Chiu C, et al.
Biologicals
. 2025 Jan;
90():101818.
PMID: 39824043
Inno4Vac, a public-private partnership funded by the IMI2/EU/EFPIA Joint Undertaking (IMI2 JU), brings together academic institutions, SMEs, and pharmaceutical companies to accelerate and de-risk vaccine development. The project has made...
2.
Bansal A, Trieu M, Mohn K, Madsen A, Olofsson J, Sandnes H, et al.
Front Public Health
. 2023 Aug;
11:1164326.
PMID: 37546332
Background: Preventing infection in healthcare workers (HCWs) is crucial for protecting healthcare systems during the COVID-19 pandemic. Here, we investigated the seroepidemiology of SARS-CoV-2 in HCWs in Norway with low-transmission...
3.
Hansen L, Brokstad K, Bansal A, Zhou F, Bredholt G, Onyango T, et al.
Vaccine X
. 2023 Jan;
13:100262.
PMID: 36643855
Objectives: Elderly are an understudied, high-risk group vulnerable to severe COVID-19. We comprehensively analyzed the durability of humoral and cellular immune responses after BNT162b2 vaccination and SARS-CoV-2 infection in elderly...
4.
Fjelltveit E, Blomberg B, Kuwelker K, Zhou F, Onyango T, Brokstad K, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e60-e70.
PMID: 35959897
Background: The burden and duration of persistent symptoms after nonsevere coronavirus disease 2019 (COVID-19) remains uncertain. This study aimed to assess postinfection symptom trajectories in home-isolated COVID-19 cases compared with...
5.
Ertesvag N, Xiao J, Zhou F, Ljostveit S, Sandnes H, Lartey S, et al.
Commun Med (Lond)
. 2022 May;
2:36.
PMID: 35603265
Background: Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection. Methods: Firstly, we developed a receptor-binding domain-specific haemagglutination test...
6.
Bansal A, Trieu M, Mohn K, Cox R
Front Immunol
. 2021 Oct;
12:744774.
PMID: 34691051
Annual influenza vaccination is often recommended for pregnant women and young children to reduce the risk of severe influenza. However, most studies investigating the safety, immunogenicity, and efficacy or effectiveness...
7.
Trieu M, Bansal A, Madsen A, Zhou F, Saevik M, Vahokoski J, et al.
J Infect Dis
. 2020 Nov;
223(4):589-599.
PMID: 33247924
Background: During the coronavirus disease 2019 (COVID-19) pandemic, many countries experienced infection in health care workers (HCW) due to overburdened health care systems. Whether infected HCW acquire protective immunity against...
8.
Fjelltveit E, Cox R, Ostensjo J, Blomberg B, Ebbesen M, Langeland N, et al.
J Infect Dis
. 2020 Nov;
226(1):97-108.
PMID: 33151320
Background: Influenza is difficult to distinguish clinically from other acute respiratory infections. Rapid laboratory diagnosis can help initiate early effective antiviral treatment and isolation. Implementing a novel point-of-care test (POCT)...
9.
Venkatesan S, Myles P, Bolton K, Muthuri S, Al Khuwaitir T, Anovadiya A, et al.
J Infect Dis
. 2019 Jul;
221(3):356-366.
PMID: 31314899
Background: The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear. Methods: We conducted a one-stage individual participant data (IPD) meta-analysis...
10.
Islam S, Zhou F, Lartey S, Mohn K, Krammer F, Cox R, et al.
Scand J Immunol
. 2019 Jul;
90(4):e12801.
PMID: 31269273
Influenza virus is a major respiratory pathogen, and vaccination is the main method of prophylaxis. In 2012, the trivalent live attenuated influenza vaccine (LAIV) was licensed in Europe for use...